This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

About

Efficacy

Safety & Tolerability

Real World Experience

Support & Resources

Information on how to access XELJANZ®▼ (tofacitinib citrate) prescribing information and adverse event reporting can be found at the bottom of the page.

PsA Video Resources

Dr Richard Smith discusses his experience prescribing XELJANZ in Psoriatic Arthritis

Explore More

Dr Richard Smith presents patient case studies to discuss his experience prescribing XELJANZ in Psoriatic Arthritis


Header

References

  1. Item


Explore More


Explore More

Lorem ipsum dolor sit amet, consectetur adipiscing elit feugiat accumsan vitae et purus.

Header

This text is for block level content. P tags can go in here too

Header

This text is for block level content. P tags can go in here too

Dosing in PsA

Visit page

Announcement Title

XELJANZ Risk Minimisation Programme (RMP) materials, including a Patient Alert Card, Prescriber Checklists and a Prescriber Brochure are available from https://www.medicines.org.uk/emc/. Patients treated with XELJANZ should be given the Patient Alert Card.

UK Clinician's Experience

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No